Langiprav

Pravastatin, the active ingredient in Langiprav, is a statin presented as an oral tablet for oral use. It lowers elevated cholesterol and is indicated for hypercholesterolemia and for reducing cardiovascular risk, including primary hyperlipidemia and secondary prevention after myocardial infarction.

GNH USA supplies Langiprav as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets with a focus on consistent batch quality and regulatory compliance.

Langiprav (pravastatin) acts on lipid metabolism to lower cholesterol levels.

- Hypercholesterolemia: reduces low‑density lipoprotein cholesterol and total cholesterol. - Primary hyperlipidemia: improves overall lipid profile by lowering LDL‑C and triglycerides. - Cardiovascular disease prevention: decreases the risk of myocardial infarction, stroke and other atherosclerotic events.

Pravastatin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Gastrointestinal upset: includes nausea, abdominal discomfort or diarrhea. - Myalgia: muscle aches without significant weakness.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown that may lead to renal impairment. - Elevated liver enzymes: indicates possible hepatocellular injury. - Severe allergic reaction: includes rash, angioedema or anaphylaxis.

Before initiating therapy, clinicians should evaluate relevant safety factors.

- Liver function monitoring: obtain baseline transaminases and repeat periodically. - Renal function assessment: adjust use in patients with severe renal impairment. - Drug interaction review: check for concomitant medications that affect statin metabolism. - Elderly patients: start with the lowest effective dose and monitor tolerance. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Pravastatin may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Cyclosporine: markedly increases pravastatin plasma concentrations. - Gemfibrozil: raises risk of myopathy and rhabdomyolysis. - Clarithromycin: can elevate pravastatin levels leading to toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Amiodarone: may increase pravastatin exposure; observe for muscle symptoms.